186 related articles for article (PubMed ID: 17062962)
41. Studies on curative efficacy of monoterpene eugenol on anti- leukemic drug arsenic trioxide induced cardiotoxicity.
Binu P; Priya N; Abhilash S; Vineetha RC; Nair RH
Biomed Pharmacother; 2017 Jul; 91():559-566. PubMed ID: 28494415
[TBL] [Abstract][Full Text] [Related]
42. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
Huang BT; Zeng QC; Gurung A; Zhao WH; Xiao Z; Li BS
Med Oncol; 2012 Sep; 29(3):2088-94. PubMed ID: 22038728
[TBL] [Abstract][Full Text] [Related]
43. Cardiac toxicity of arsenic trioxide.
Barbey JT
Blood; 2001 Sep; 98(5):1632; author reply 1633-4. PubMed ID: 11547771
[No Abstract] [Full Text] [Related]
44. [Effect of the tetra-arsenic tetra-sulfide (As4S4) on the corrected QT interval in the treatment of acute promyelocytic leukemia].
Shen JC; Liu KY; Jiang B; Lu XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):359-61. PubMed ID: 15308017
[TBL] [Abstract][Full Text] [Related]
45. Arsenic compound approved as cancer chemotherapy agent.
Miller JL
Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
[No Abstract] [Full Text] [Related]
46. Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation.
Lu HR; Vlaminckx E; Gallacher DJ
J Pharmacol Toxicol Methods; 2008; 57(1):1-8. PubMed ID: 17964190
[TBL] [Abstract][Full Text] [Related]
47. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
48. Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.
Wan X; Dennis AT; Obejero-Paz C; Overholt JL; Heredia-Moya J; Kirk KL; Ficker E
J Biol Chem; 2011 Jan; 286(4):2843-52. PubMed ID: 21097842
[TBL] [Abstract][Full Text] [Related]
49. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
50. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
51. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
52. Ancient remedy performs new tricks.
Mervis J
Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
[No Abstract] [Full Text] [Related]
53. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
54. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
55. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Carney DA
Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
[No Abstract] [Full Text] [Related]
56. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
[No Abstract] [Full Text] [Related]
57. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
58. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
59. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
60. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Zhang X; Yang L; Qiao Z
Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]